nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—atopic dermatitis—psoriasis	0.506	1	CtDrD
Tacrolimus—PPP3CA—Cyclosporine—psoriasis	0.138	0.416	CbGbCtD
Tacrolimus—FKBP1A—Cyclosporine—psoriasis	0.0574	0.173	CbGbCtD
Tacrolimus—ALB—Acitretin—psoriasis	0.0146	0.044	CbGbCtD
Tacrolimus—CYP3A5—Beclomethasone—psoriasis	0.0138	0.0416	CbGbCtD
Tacrolimus—ALB—Mycophenolate mofetil—psoriasis	0.00684	0.0206	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00588	0.0177	CbGbCtD
Tacrolimus—CYP3A7—Hydrocortisone—psoriasis	0.00588	0.0177	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.00556	0.0167	CbGbCtD
Tacrolimus—CYP3A7—Cyclosporine—psoriasis	0.00556	0.0167	CbGbCtD
Tacrolimus—CYP3A5—Mycophenolate mofetil—psoriasis	0.0055	0.0165	CbGbCtD
Tacrolimus—ALB—Prednisone—psoriasis	0.00547	0.0165	CbGbCtD
Tacrolimus—CYP3A4—Calcitriol—psoriasis	0.0048	0.0144	CbGbCtD
Tacrolimus—CYP3A5—Hydrocortisone—psoriasis	0.00441	0.0133	CbGbCtD
Tacrolimus—CYP3A5—Cyclosporine—psoriasis	0.00417	0.0125	CbGbCtD
Tacrolimus—CYP3A4—Methoxsalen—psoriasis	0.00373	0.0112	CbGbCtD
Tacrolimus—CYP3A7—Dexamethasone—psoriasis	0.00366	0.011	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00366	0.011	CbGbCtD
Tacrolimus—ABCB1—Mycophenolate mofetil—psoriasis	0.00358	0.0108	CbGbCtD
Tacrolimus—ABCB1—Betamethasone—psoriasis	0.00307	0.00924	CbGbCtD
Tacrolimus—ABCB1—Prednisolone—psoriasis	0.00303	0.00912	CbGbCtD
Tacrolimus—ABCB1—Hydrocortisone—psoriasis	0.00287	0.00864	CbGbCtD
Tacrolimus—ABCB1—Prednisone—psoriasis	0.00286	0.00861	CbGbCtD
Tacrolimus—CYP3A5—Dexamethasone—psoriasis	0.00274	0.00826	CbGbCtD
Tacrolimus—ALB—Methotrexate—psoriasis	0.00274	0.00826	CbGbCtD
Tacrolimus—ABCB1—Cyclosporine—psoriasis	0.00271	0.00816	CbGbCtD
Tacrolimus—CYP3A4—Cholecalciferol—psoriasis	0.00247	0.00744	CbGbCtD
Tacrolimus—CYP3A4—Mycophenolate mofetil—psoriasis	0.00214	0.00645	CbGbCtD
Tacrolimus—CYP3A4—Triamcinolone—psoriasis	0.00214	0.00645	CbGbCtD
Tacrolimus—CYP3A4—Betamethasone—psoriasis	0.00184	0.00554	CbGbCtD
Tacrolimus—CYP3A4—Prednisolone—psoriasis	0.00182	0.00546	CbGbCtD
Tacrolimus—ABCB1—Dexamethasone—psoriasis	0.00179	0.00537	CbGbCtD
Tacrolimus—CYP3A4—Hydrocortisone—psoriasis	0.00172	0.00518	CbGbCtD
Tacrolimus—CYP3A4—Prednisone—psoriasis	0.00171	0.00516	CbGbCtD
Tacrolimus—CYP3A4—Cyclosporine—psoriasis	0.00163	0.00489	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—psoriasis	0.00144	0.00432	CbGbCtD
Tacrolimus—CYP3A4—Dexamethasone—psoriasis	0.00107	0.00322	CbGbCtD
Tacrolimus—MTOR—BDNF signaling pathway—JUN—psoriasis	2.76e-05	0.00102	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—SOCS1—psoriasis	2.67e-05	0.000983	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—JUN—psoriasis	2.66e-05	0.000981	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—NFKB1—psoriasis	2.66e-05	0.00098	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NDUFA5—psoriasis	2.64e-05	0.000973	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HCAR2—psoriasis	2.63e-05	0.000969	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.59e-05	0.000954	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—TYK2—psoriasis	2.58e-05	0.000951	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—DDX58—psoriasis	2.57e-05	0.000948	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	2.56e-05	0.000945	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	2.56e-05	0.000944	CbGpPWpGaD
Tacrolimus—MTOR—IRS-mediated signalling—IL6—psoriasis	2.54e-05	0.000938	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—JUN—psoriasis	2.54e-05	0.000936	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—psoriasis	2.51e-05	0.000927	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events—IL6—psoriasis	2.47e-05	0.000913	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—psoriasis	2.45e-05	0.000904	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—NFKB1—psoriasis	2.44e-05	0.000899	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—STAT3—psoriasis	2.43e-05	0.000896	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCL20—psoriasis	2.43e-05	0.000895	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—NFKBIA—psoriasis	2.41e-05	0.000887	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HLA-E—psoriasis	2.39e-05	0.000881	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—STAT3—psoriasis	2.39e-05	0.000881	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—IL6—psoriasis	2.39e-05	0.000881	CbGpPWpGaD
Tacrolimus—MTOR—Insulin receptor signalling cascade—IL6—psoriasis	2.39e-05	0.000881	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD8A—psoriasis	2.36e-05	0.000872	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	2.36e-05	0.000871	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—psoriasis	2.35e-05	0.000866	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	2.34e-05	0.000864	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.33e-05	0.00086	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CD4—psoriasis	2.33e-05	0.00086	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.33e-05	0.000859	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	2.32e-05	0.000857	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-E—psoriasis	2.29e-05	0.000846	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TAGAP—psoriasis	2.28e-05	0.00084	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-B—psoriasis	2.27e-05	0.000839	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	2.25e-05	0.000831	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP2S1—psoriasis	2.24e-05	0.000827	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IFNG—psoriasis	2.22e-05	0.00082	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.22e-05	0.000819	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—STAT3—psoriasis	2.18e-05	0.000806	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—psoriasis	2.17e-05	0.000802	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—psoriasis	2.15e-05	0.000792	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—psoriasis	2.12e-05	0.00078	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-A—psoriasis	2.11e-05	0.000777	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—JUN—psoriasis	2.09e-05	0.000769	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—NFKB1—psoriasis	2.09e-05	0.000769	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.07e-05	0.000762	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—STAT3—psoriasis	2.03e-05	0.000747	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CRP—psoriasis	2.01e-05	0.000741	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—NFKB1—psoriasis	2.01e-05	0.000741	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—IL6—psoriasis	2e-05	0.000737	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—SOCS1—psoriasis	2e-05	0.000736	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—IL6—psoriasis	1.98e-05	0.000732	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—STAT3—psoriasis	1.98e-05	0.000731	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—TYK2—psoriasis	1.97e-05	0.000727	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ITGAL—psoriasis	1.95e-05	0.000718	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HLA-A—psoriasis	1.95e-05	0.000717	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.94e-05	0.000715	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	1.94e-05	0.000714	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HLA-DRB1—psoriasis	1.92e-05	0.00071	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—SOCS1—psoriasis	1.92e-05	0.000707	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NDUFA5—psoriasis	1.91e-05	0.000703	CbGpPWpGaD
Tacrolimus—ALB—Platelet degranulation—VEGFA—psoriasis	1.9e-05	0.0007	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TNF—psoriasis	1.9e-05	0.000699	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IL6—psoriasis	1.88e-05	0.000694	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ICAM1—psoriasis	1.85e-05	0.000681	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—NFKBIA—psoriasis	1.83e-05	0.000676	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—CXCL8—psoriasis	1.83e-05	0.000675	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—ITGAL—psoriasis	1.83e-05	0.000673	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—REL—psoriasis	1.82e-05	0.000672	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—APOE—psoriasis	1.82e-05	0.00067	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	1.81e-05	0.000667	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	1.79e-05	0.000662	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFIH1—psoriasis	1.77e-05	0.000652	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—psoriasis	1.76e-05	0.000647	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SOCS1—psoriasis	1.72e-05	0.000636	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.7e-05	0.000628	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HLA-B—psoriasis	1.7e-05	0.000628	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—JUN—psoriasis	1.7e-05	0.000627	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD8A—psoriasis	1.7e-05	0.000627	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—IL6—psoriasis	1.7e-05	0.000626	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—NOS2—psoriasis	1.69e-05	0.000624	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.68e-05	0.000619	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-C—psoriasis	1.68e-05	0.000618	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TP53—psoriasis	1.67e-05	0.000617	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TNFAIP3—psoriasis	1.66e-05	0.000611	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—TYK2—psoriasis	1.64e-05	0.000606	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NDUFA5—psoriasis	1.64e-05	0.000606	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—NFKB1—psoriasis	1.64e-05	0.000604	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-B—psoriasis	1.63e-05	0.000603	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—IL6—psoriasis	1.62e-05	0.000599	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP2S1—psoriasis	1.62e-05	0.000598	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—IL6—psoriasis	1.6e-05	0.000589	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—NFKB1—psoriasis	1.54e-05	0.000566	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.53e-05	0.000565	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL6—psoriasis	1.53e-05	0.000564	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—IL6—psoriasis	1.53e-05	0.000563	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.53e-05	0.000563	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—IL6—psoriasis	1.52e-05	0.00056	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-A—psoriasis	1.51e-05	0.000559	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—IL6—psoriasis	1.51e-05	0.000557	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HLA-A—psoriasis	1.51e-05	0.000556	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.51e-05	0.000556	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CRP—psoriasis	1.5e-05	0.000555	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—IL6—psoriasis	1.5e-05	0.000555	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—TYK2—psoriasis	1.5e-05	0.000554	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—VEGFA—psoriasis	1.49e-05	0.000548	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—STAT3—psoriasis	1.47e-05	0.000543	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.46e-05	0.000537	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TNF—psoriasis	1.44e-05	0.000531	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NDUFA5—psoriasis	1.44e-05	0.000531	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.43e-05	0.000528	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CXCL8—psoriasis	1.43e-05	0.000528	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—IL6—psoriasis	1.41e-05	0.000522	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	1.41e-05	0.000522	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—IL6—psoriasis	1.41e-05	0.000522	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—APOE—psoriasis	1.41e-05	0.000519	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IFNG—psoriasis	1.41e-05	0.000518	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—IL6—psoriasis	1.4e-05	0.000517	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP2S1—psoriasis	1.4e-05	0.000515	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-E—psoriasis	1.39e-05	0.000513	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—IL6—psoriasis	1.39e-05	0.000513	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—TYK2—psoriasis	1.39e-05	0.000511	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-DRB1—psoriasis	1.38e-05	0.00051	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—IL6—psoriasis	1.38e-05	0.00051	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—STAT3—psoriasis	1.38e-05	0.000509	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NFKBIA—psoriasis	1.37e-05	0.000506	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL20—psoriasis	1.36e-05	0.000503	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD4—psoriasis	1.36e-05	0.000501	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.34e-05	0.000493	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SOCS1—psoriasis	1.34e-05	0.000493	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ICAM1—psoriasis	1.33e-05	0.00049	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NFKBIA—psoriasis	1.32e-05	0.000486	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NOS2—psoriasis	1.31e-05	0.000484	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.28e-05	0.00047	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—APOE—psoriasis	1.27e-05	0.000469	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—LEP—psoriasis	1.27e-05	0.000469	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—IL6—psoriasis	1.26e-05	0.000465	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD4—psoriasis	1.25e-05	0.000462	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.25e-05	0.000462	CbGpPWpGaD
Tacrolimus—Dermatitis—Mycophenolic acid—psoriasis	1.24e-05	9.24e-05	CcSEcCtD
Tacrolimus—Pain—Prednisolone—psoriasis	1.24e-05	9.23e-05	CcSEcCtD
Tacrolimus—Hepatitis—Methotrexate—psoriasis	1.24e-05	9.23e-05	CcSEcCtD
Tacrolimus—Haemorrhage—Methotrexate—psoriasis	1.24e-05	9.23e-05	CcSEcCtD
Tacrolimus—Urticaria—Mycophenolate mofetil—psoriasis	1.23e-05	9.2e-05	CcSEcCtD
Tacrolimus—Headache—Mycophenolic acid—psoriasis	1.23e-05	9.19e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Hydrocortisone—psoriasis	1.23e-05	9.17e-05	CcSEcCtD
Tacrolimus—Pharyngitis—Methotrexate—psoriasis	1.23e-05	9.16e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Mycophenolate mofetil—psoriasis	1.23e-05	9.15e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Mycophenolate mofetil—psoriasis	1.23e-05	9.15e-05	CcSEcCtD
Tacrolimus—Urinary tract disorder—Methotrexate—psoriasis	1.22e-05	9.12e-05	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—CYP2S1—psoriasis	1.22e-05	0.000451	CbGpPWpGaD
Tacrolimus—Gastrointestinal disorder—Hydrocortisone—psoriasis	1.22e-05	9.11e-05	CcSEcCtD
Tacrolimus—Fatigue—Hydrocortisone—psoriasis	1.22e-05	9.09e-05	CcSEcCtD
Tacrolimus—Vision blurred—Prednisone—psoriasis	1.22e-05	9.06e-05	CcSEcCtD
Tacrolimus—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.22e-05	0.000448	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—JUN—psoriasis	1.22e-05	0.000448	CbGpPWpGaD
Tacrolimus—Urethral disorder—Methotrexate—psoriasis	1.21e-05	9.05e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Triamcinolone—psoriasis	1.21e-05	9.05e-05	CcSEcCtD
Tacrolimus—Pain—Hydrocortisone—psoriasis	1.21e-05	9.02e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Betamethasone—psoriasis	1.21e-05	9.01e-05	CcSEcCtD
Tacrolimus—Oedema—Betamethasone—psoriasis	1.21e-05	9.01e-05	CcSEcCtD
Tacrolimus—Oedema—Dexamethasone—psoriasis	1.21e-05	9.01e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Dexamethasone—psoriasis	1.21e-05	9.01e-05	CcSEcCtD
Tacrolimus—Insomnia—Triamcinolone—psoriasis	1.21e-05	8.98e-05	CcSEcCtD
Tacrolimus—Infection—Betamethasone—psoriasis	1.2e-05	8.95e-05	CcSEcCtD
Tacrolimus—Infection—Dexamethasone—psoriasis	1.2e-05	8.95e-05	CcSEcCtD
Tacrolimus—Ill-defined disorder—Prednisone—psoriasis	1.2e-05	8.92e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Triamcinolone—psoriasis	1.2e-05	8.92e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisolone—psoriasis	1.19e-05	8.9e-05	CcSEcCtD
Tacrolimus—Visual impairment—Methotrexate—psoriasis	1.19e-05	8.9e-05	CcSEcCtD
Tacrolimus—Anaemia—Prednisone—psoriasis	1.19e-05	8.89e-05	CcSEcCtD
Tacrolimus—Shock—Betamethasone—psoriasis	1.19e-05	8.87e-05	CcSEcCtD
Tacrolimus—Shock—Dexamethasone—psoriasis	1.19e-05	8.87e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Triamcinolone—psoriasis	1.19e-05	8.85e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Betamethasone—psoriasis	1.19e-05	8.84e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Dexamethasone—psoriasis	1.19e-05	8.84e-05	CcSEcCtD
Tacrolimus—Agitation—Prednisone—psoriasis	1.19e-05	8.84e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—NFKBIA—psoriasis	1.18e-05	0.000437	CbGpPWpGaD
Tacrolimus—Thrombocytopenia—Betamethasone—psoriasis	1.18e-05	8.82e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Dexamethasone—psoriasis	1.18e-05	8.82e-05	CcSEcCtD
Tacrolimus—Tachycardia—Dexamethasone—psoriasis	1.18e-05	8.79e-05	CcSEcCtD
Tacrolimus—Tachycardia—Betamethasone—psoriasis	1.18e-05	8.79e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Cyclosporine—psoriasis	1.17e-05	8.74e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Triamcinolone—psoriasis	1.17e-05	8.74e-05	CcSEcCtD
Tacrolimus—Erythema multiforme—Methotrexate—psoriasis	1.17e-05	8.73e-05	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—NFKB1—psoriasis	1.17e-05	0.000431	CbGpPWpGaD
Tacrolimus—Nausea—Mycophenolic acid—psoriasis	1.17e-05	8.71e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Dexamethasone—psoriasis	1.17e-05	8.71e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Betamethasone—psoriasis	1.17e-05	8.71e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Hydrocortisone—psoriasis	1.17e-05	8.69e-05	CcSEcCtD
Tacrolimus—Malaise—Prednisone—psoriasis	1.16e-05	8.67e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—SOCS1—psoriasis	1.16e-05	0.000429	CbGpPWpGaD
Tacrolimus—Vertigo—Prednisone—psoriasis	1.16e-05	8.64e-05	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—psoriasis	1.16e-05	8.63e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Hydrocortisone—psoriasis	1.16e-05	8.62e-05	CcSEcCtD
Tacrolimus—Syncope—Prednisone—psoriasis	1.16e-05	8.62e-05	CcSEcCtD
Tacrolimus—Tinnitus—Methotrexate—psoriasis	1.16e-05	8.61e-05	CcSEcCtD
Tacrolimus—Anorexia—Dexamethasone—psoriasis	1.15e-05	8.59e-05	CcSEcCtD
Tacrolimus—Anorexia—Betamethasone—psoriasis	1.15e-05	8.59e-05	CcSEcCtD
Tacrolimus—Urticaria—Prednisolone—psoriasis	1.15e-05	8.58e-05	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—psoriasis	1.15e-05	8.57e-05	CcSEcCtD
Tacrolimus—Fatigue—Triamcinolone—psoriasis	1.15e-05	8.56e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Mycophenolate mofetil—psoriasis	1.14e-05	8.53e-05	CcSEcCtD
Tacrolimus—Asthenia—Cyclosporine—psoriasis	1.14e-05	8.51e-05	CcSEcCtD
Tacrolimus—Pain—Triamcinolone—psoriasis	1.14e-05	8.49e-05	CcSEcCtD
Tacrolimus—Loss of consciousness—Prednisone—psoriasis	1.13e-05	8.45e-05	CcSEcCtD
Tacrolimus—Hypotension—Dexamethasone—psoriasis	1.13e-05	8.42e-05	CcSEcCtD
Tacrolimus—Hypotension—Betamethasone—psoriasis	1.13e-05	8.42e-05	CcSEcCtD
Tacrolimus—Pruritus—Cyclosporine—psoriasis	1.13e-05	8.4e-05	CcSEcCtD
Tacrolimus—Urticaria—Hydrocortisone—psoriasis	1.12e-05	8.38e-05	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—psoriasis	1.12e-05	8.38e-05	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—TYK2—psoriasis	1.12e-05	0.000415	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—psoriasis	1.12e-05	0.000414	CbGpPWpGaD
Tacrolimus—Immune system disorder—Methotrexate—psoriasis	1.12e-05	8.34e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Hydrocortisone—psoriasis	1.12e-05	8.34e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Hydrocortisone—psoriasis	1.12e-05	8.34e-05	CcSEcCtD
Tacrolimus—Convulsion—Prednisone—psoriasis	1.12e-05	8.33e-05	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—psoriasis	1.12e-05	8.32e-05	CcSEcCtD
Tacrolimus—Asthenia—Mycophenolate mofetil—psoriasis	1.11e-05	8.31e-05	CcSEcCtD
Tacrolimus—Hypertension—Prednisone—psoriasis	1.11e-05	8.3e-05	CcSEcCtD
Tacrolimus—Chills—Methotrexate—psoriasis	1.11e-05	8.28e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Dexamethasone—psoriasis	1.1e-05	8.21e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Betamethasone—psoriasis	1.1e-05	8.21e-05	CcSEcCtD
Tacrolimus—Pruritus—Mycophenolate mofetil—psoriasis	1.1e-05	8.19e-05	CcSEcCtD
Tacrolimus—Myalgia—Prednisone—psoriasis	1.1e-05	8.19e-05	CcSEcCtD
Tacrolimus—Arthralgia—Prednisone—psoriasis	1.1e-05	8.19e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Triamcinolone—psoriasis	1.1e-05	8.18e-05	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—CARM1—psoriasis	1.1e-05	0.000404	CbGpPWpGaD
Tacrolimus—Anxiety—Prednisone—psoriasis	1.09e-05	8.16e-05	CcSEcCtD
Tacrolimus—Alopecia—Methotrexate—psoriasis	1.09e-05	8.16e-05	CcSEcCtD
Tacrolimus—Insomnia—Betamethasone—psoriasis	1.09e-05	8.15e-05	CcSEcCtD
Tacrolimus—Insomnia—Dexamethasone—psoriasis	1.09e-05	8.15e-05	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	1.09e-05	8.13e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Cyclosporine—psoriasis	1.09e-05	8.12e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Betamethasone—psoriasis	1.09e-05	8.09e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Dexamethasone—psoriasis	1.09e-05	8.09e-05	CcSEcCtD
Tacrolimus—Discomfort—Prednisone—psoriasis	1.09e-05	8.09e-05	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—psoriasis	1.09e-05	8.09e-05	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—psoriasis	1.08e-05	8.04e-05	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—psoriasis	1.08e-05	8.04e-05	CcSEcCtD
Tacrolimus—FKBP1A—Disease—TYK2—psoriasis	1.07e-05	0.000396	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Prednisolone—psoriasis	1.07e-05	7.96e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Dexamethasone—psoriasis	1.06e-05	7.93e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Betamethasone—psoriasis	1.06e-05	7.93e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Mycophenolate mofetil—psoriasis	1.06e-05	7.92e-05	CcSEcCtD
Tacrolimus—Urticaria—Triamcinolone—psoriasis	1.06e-05	7.89e-05	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—psoriasis	1.06e-05	7.87e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Triamcinolone—psoriasis	1.05e-05	7.85e-05	CcSEcCtD
Tacrolimus—Dizziness—Cyclosporine—psoriasis	1.05e-05	7.85e-05	CcSEcCtD
Tacrolimus—Oedema—Prednisone—psoriasis	1.05e-05	7.85e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Prednisone—psoriasis	1.05e-05	7.85e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Betamethasone—psoriasis	1.05e-05	7.83e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Dexamethasone—psoriasis	1.05e-05	7.83e-05	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—STAT3—psoriasis	1.05e-05	0.000388	CbGpPWpGaD
Tacrolimus—Infection—Prednisone—psoriasis	1.05e-05	7.8e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Betamethasone—psoriasis	1.04e-05	7.78e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Dexamethasone—psoriasis	1.04e-05	7.78e-05	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—psoriasis	1.04e-05	7.77e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Hydrocortisone—psoriasis	1.04e-05	7.77e-05	CcSEcCtD
Tacrolimus—Fatigue—Betamethasone—psoriasis	1.04e-05	7.77e-05	CcSEcCtD
Tacrolimus—Fatigue—Dexamethasone—psoriasis	1.04e-05	7.77e-05	CcSEcCtD
Tacrolimus—Shock—Prednisone—psoriasis	1.04e-05	7.72e-05	CcSEcCtD
Tacrolimus—Pain—Betamethasone—psoriasis	1.03e-05	7.71e-05	CcSEcCtD
Tacrolimus—Pain—Dexamethasone—psoriasis	1.03e-05	7.71e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Prednisone—psoriasis	1.03e-05	7.7e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—CD8A—psoriasis	1.03e-05	0.00038	CbGpPWpGaD
Tacrolimus—Tachycardia—Prednisone—psoriasis	1.03e-05	7.66e-05	CcSEcCtD
Tacrolimus—Dizziness—Mycophenolate mofetil—psoriasis	1.03e-05	7.66e-05	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—IL6—psoriasis	1.03e-05	0.000379	CbGpPWpGaD
Tacrolimus—Skin disorder—Prednisone—psoriasis	1.02e-05	7.62e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Prednisone—psoriasis	1.02e-05	7.59e-05	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—psoriasis	1.02e-05	7.57e-05	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—CD4—psoriasis	1.02e-05	0.000375	CbGpPWpGaD
Tacrolimus—Asthenia—Hydrocortisone—psoriasis	1.02e-05	7.57e-05	CcSEcCtD
Tacrolimus—Vomiting—Cyclosporine—psoriasis	1.01e-05	7.55e-05	CcSEcCtD
Tacrolimus—Rash—Cyclosporine—psoriasis	1e-05	7.48e-05	CcSEcCtD
Tacrolimus—Anorexia—Prednisone—psoriasis	1e-05	7.48e-05	CcSEcCtD
Tacrolimus—Dermatitis—Cyclosporine—psoriasis	1e-05	7.48e-05	CcSEcCtD
Tacrolimus—Pruritus—Hydrocortisone—psoriasis	1e-05	7.46e-05	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—psoriasis	1e-05	7.46e-05	CcSEcCtD
Tacrolimus—Headache—Cyclosporine—psoriasis	9.98e-06	7.43e-05	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—psoriasis	9.97e-06	7.43e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Betamethasone—psoriasis	9.97e-06	7.43e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Dexamethasone—psoriasis	9.97e-06	7.43e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—HLA-B—psoriasis	9.92e-06	0.000366	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Betamethasone—psoriasis	9.89e-06	7.37e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Dexamethasone—psoriasis	9.89e-06	7.37e-05	CcSEcCtD
Tacrolimus—Vomiting—Mycophenolate mofetil—psoriasis	9.88e-06	7.36e-05	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—LEP—psoriasis	9.86e-06	0.000364	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—APOE—psoriasis	9.86e-06	0.000364	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Triamcinolone—psoriasis	9.82e-06	7.32e-05	CcSEcCtD
Tacrolimus—Rash—Mycophenolate mofetil—psoriasis	9.8e-06	7.3e-05	CcSEcCtD
Tacrolimus—Dermatitis—Mycophenolate mofetil—psoriasis	9.79e-06	7.29e-05	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—CD4—psoriasis	9.76e-06	0.00036	CbGpPWpGaD
Tacrolimus—Headache—Mycophenolate mofetil—psoriasis	9.73e-06	7.25e-05	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—psoriasis	9.73e-06	7.25e-05	CcSEcCtD
Tacrolimus—FKBP1A—Disease—CD4—psoriasis	9.72e-06	0.000358	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TYK2—psoriasis	9.71e-06	0.000358	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—STAT3—psoriasis	9.7e-06	0.000358	CbGpPWpGaD
Tacrolimus—Vertigo—Methotrexate—psoriasis	9.69e-06	7.22e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Hydrocortisone—psoriasis	9.69e-06	7.22e-05	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—psoriasis	9.65e-06	7.19e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—IL6—psoriasis	9.64e-06	0.000355	CbGpPWpGaD
Tacrolimus—Urticaria—Dexamethasone—psoriasis	9.61e-06	7.16e-05	CcSEcCtD
Tacrolimus—Urticaria—Betamethasone—psoriasis	9.61e-06	7.16e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Prednisone—psoriasis	9.6e-06	7.15e-05	CcSEcCtD
Tacrolimus—Dizziness—Prednisolone—psoriasis	9.59e-06	7.14e-05	CcSEcCtD
Tacrolimus—Asthenia—Triamcinolone—psoriasis	9.56e-06	7.13e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Betamethasone—psoriasis	9.56e-06	7.12e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Dexamethasone—psoriasis	9.56e-06	7.12e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Betamethasone—psoriasis	9.56e-06	7.12e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Dexamethasone—psoriasis	9.56e-06	7.12e-05	CcSEcCtD
Tacrolimus—Insomnia—Prednisone—psoriasis	9.53e-06	7.1e-05	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	9.48e-06	0.00035	CbGpPWpGaD
Tacrolimus—Nausea—Cyclosporine—psoriasis	9.46e-06	7.05e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Prednisone—psoriasis	9.46e-06	7.05e-05	CcSEcCtD
Tacrolimus—Pruritus—Triamcinolone—psoriasis	9.43e-06	7.03e-05	CcSEcCtD
Tacrolimus—Cough—Methotrexate—psoriasis	9.41e-06	7.01e-05	CcSEcCtD
Tacrolimus—Dizziness—Hydrocortisone—psoriasis	9.36e-06	6.97e-05	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—psoriasis	9.35e-06	6.96e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Prednisone—psoriasis	9.27e-06	6.91e-05	CcSEcCtD
Tacrolimus—Nausea—Mycophenolate mofetil—psoriasis	9.23e-06	6.88e-05	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—NFKBIA—psoriasis	9.19e-06	0.000339	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-A—psoriasis	9.19e-06	0.000339	CbGpPWpGaD
Tacrolimus—Arthralgia—Methotrexate—psoriasis	9.18e-06	6.84e-05	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—psoriasis	9.18e-06	6.84e-05	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—psoriasis	9.18e-06	6.84e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Prednisone—psoriasis	9.16e-06	6.82e-05	CcSEcCtD
Tacrolimus—Rash—Prednisolone—psoriasis	9.14e-06	6.81e-05	CcSEcCtD
Tacrolimus—Dermatitis—Prednisolone—psoriasis	9.13e-06	6.8e-05	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	9.13e-06	0.000337	CbGpPWpGaD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.12e-06	6.79e-05	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—JUN—psoriasis	9.1e-06	0.000336	CbGpPWpGaD
Tacrolimus—Fatigue—Prednisone—psoriasis	9.08e-06	6.77e-05	CcSEcCtD
Tacrolimus—Headache—Prednisolone—psoriasis	9.08e-06	6.77e-05	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—psoriasis	9.07e-06	6.76e-05	CcSEcCtD
Tacrolimus—Constipation—Prednisone—psoriasis	9.01e-06	6.71e-05	CcSEcCtD
Tacrolimus—Vomiting—Hydrocortisone—psoriasis	9e-06	6.71e-05	CcSEcCtD
Tacrolimus—Rash—Hydrocortisone—psoriasis	8.93e-06	6.65e-05	CcSEcCtD
Tacrolimus—Dermatitis—Hydrocortisone—psoriasis	8.92e-06	6.64e-05	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—psoriasis	8.88e-06	6.61e-05	CcSEcCtD
Tacrolimus—Headache—Hydrocortisone—psoriasis	8.87e-06	6.61e-05	CcSEcCtD
Tacrolimus—CYP3A4—Metabolism—NDUFA5—psoriasis	8.86e-06	0.000327	CbGpPWpGaD
Tacrolimus—Dizziness—Triamcinolone—psoriasis	8.81e-06	6.57e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—psoriasis	8.8e-06	6.56e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—CRP—psoriasis	8.76e-06	0.000323	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NFKB1—psoriasis	8.76e-06	0.000323	CbGpPWpGaD
Tacrolimus—Infection—Methotrexate—psoriasis	8.75e-06	6.52e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisone—psoriasis	8.68e-06	6.47e-05	CcSEcCtD
Tacrolimus—Asthenia—Dexamethasone—psoriasis	8.68e-06	6.47e-05	CcSEcCtD
Tacrolimus—Asthenia—Betamethasone—psoriasis	8.68e-06	6.47e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—psoriasis	8.63e-06	6.43e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—psoriasis	8.62e-06	6.42e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Prednisone—psoriasis	8.61e-06	6.42e-05	CcSEcCtD
Tacrolimus—Nausea—Prednisolone—psoriasis	8.61e-06	6.41e-05	CcSEcCtD
Tacrolimus—Pruritus—Dexamethasone—psoriasis	8.56e-06	6.38e-05	CcSEcCtD
Tacrolimus—Pruritus—Betamethasone—psoriasis	8.56e-06	6.38e-05	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—psoriasis	8.55e-06	6.37e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—psoriasis	8.51e-06	6.34e-05	CcSEcCtD
Tacrolimus—MTOR—Disease—HLA-A—psoriasis	8.48e-06	0.000313	CbGpPWpGaD
Tacrolimus—Vomiting—Triamcinolone—psoriasis	8.48e-06	6.31e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—CXCL8—psoriasis	8.45e-06	0.000312	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	8.42e-06	0.00031	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NFKB1—psoriasis	8.41e-06	0.00031	CbGpPWpGaD
Tacrolimus—Nausea—Hydrocortisone—psoriasis	8.41e-06	6.26e-05	CcSEcCtD
Tacrolimus—Rash—Triamcinolone—psoriasis	8.4e-06	6.26e-05	CcSEcCtD
Tacrolimus—Dermatitis—Triamcinolone—psoriasis	8.4e-06	6.26e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—HLA-DRB1—psoriasis	8.39e-06	0.00031	CbGpPWpGaD
Tacrolimus—Anorexia—Methotrexate—psoriasis	8.39e-06	6.25e-05	CcSEcCtD
Tacrolimus—Urticaria—Prednisone—psoriasis	8.37e-06	6.23e-05	CcSEcCtD
Tacrolimus—Headache—Triamcinolone—psoriasis	8.35e-06	6.22e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Prednisone—psoriasis	8.33e-06	6.2e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Prednisone—psoriasis	8.33e-06	6.2e-05	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	8.29e-06	0.000306	CbGpPWpGaD
Tacrolimus—Diarrhoea—Betamethasone—psoriasis	8.28e-06	6.17e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Dexamethasone—psoriasis	8.28e-06	6.17e-05	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—psoriasis	8.23e-06	6.13e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—ICAM1—psoriasis	8.06e-06	0.000297	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL6—psoriasis	8.04e-06	0.000296	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—psoriasis	8.02e-06	5.98e-05	CcSEcCtD
Tacrolimus—Dizziness—Dexamethasone—psoriasis	8e-06	5.96e-05	CcSEcCtD
Tacrolimus—Dizziness—Betamethasone—psoriasis	8e-06	5.96e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—NFKBIA—psoriasis	7.99e-06	0.000295	CbGpPWpGaD
Tacrolimus—Insomnia—Methotrexate—psoriasis	7.96e-06	5.93e-05	CcSEcCtD
Tacrolimus—MTOR—Disease—APOE—psoriasis	7.92e-06	0.000292	CbGpPWpGaD
Tacrolimus—Nausea—Triamcinolone—psoriasis	7.92e-06	5.9e-05	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—CARM1—psoriasis	7.92e-06	0.000292	CbGpPWpGaD
Tacrolimus—Paraesthesia—Methotrexate—psoriasis	7.9e-06	5.89e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—JUN—psoriasis	7.86e-06	0.00029	CbGpPWpGaD
Tacrolimus—Dyspnoea—Methotrexate—psoriasis	7.85e-06	5.85e-05	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—psoriasis	7.83e-06	5.83e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Prednisone—psoriasis	7.76e-06	5.78e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—psoriasis	7.75e-06	5.77e-05	CcSEcCtD
Tacrolimus—Vomiting—Betamethasone—psoriasis	7.69e-06	5.73e-05	CcSEcCtD
Tacrolimus—Vomiting—Dexamethasone—psoriasis	7.69e-06	5.73e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Methotrexate—psoriasis	7.65e-06	5.7e-05	CcSEcCtD
Tacrolimus—Rash—Betamethasone—psoriasis	7.63e-06	5.68e-05	CcSEcCtD
Tacrolimus—Rash—Dexamethasone—psoriasis	7.63e-06	5.68e-05	CcSEcCtD
Tacrolimus—Dermatitis—Dexamethasone—psoriasis	7.62e-06	5.68e-05	CcSEcCtD
Tacrolimus—Dermatitis—Betamethasone—psoriasis	7.62e-06	5.68e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—psoriasis	7.6e-06	5.66e-05	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—psoriasis	7.59e-06	5.65e-05	CcSEcCtD
Tacrolimus—Headache—Betamethasone—psoriasis	7.58e-06	5.65e-05	CcSEcCtD
Tacrolimus—Headache—Dexamethasone—psoriasis	7.58e-06	5.65e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—NFKB1—psoriasis	7.56e-06	0.000279	CbGpPWpGaD
Tacrolimus—Asthenia—Prednisone—psoriasis	7.56e-06	5.63e-05	CcSEcCtD
Tacrolimus—CYP3A4—Metabolism—CYP2S1—psoriasis	7.54e-06	0.000278	CbGpPWpGaD
Tacrolimus—Pain—Methotrexate—psoriasis	7.53e-06	5.61e-05	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—TYK2—psoriasis	7.53e-06	0.000278	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—STAT3—psoriasis	7.52e-06	0.000278	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SOCS1—psoriasis	7.51e-06	0.000277	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NOS2—psoriasis	7.49e-06	0.000276	CbGpPWpGaD
Tacrolimus—Pruritus—Prednisone—psoriasis	7.45e-06	5.55e-05	CcSEcCtD
Tacrolimus—MTOR—Disease—NOS2—psoriasis	7.38e-06	0.000272	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL6—psoriasis	7.34e-06	0.000271	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.32e-06	0.00027	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Methotrexate—psoriasis	7.25e-06	5.4e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Prednisone—psoriasis	7.21e-06	5.37e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—psoriasis	7.2e-06	5.36e-05	CcSEcCtD
Tacrolimus—Nausea—Betamethasone—psoriasis	7.18e-06	5.35e-05	CcSEcCtD
Tacrolimus—Nausea—Dexamethasone—psoriasis	7.18e-06	5.35e-05	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	7.1e-06	0.000262	CbGpPWpGaD
Tacrolimus—Urticaria—Methotrexate—psoriasis	6.99e-06	5.21e-05	CcSEcCtD
Tacrolimus—Dizziness—Prednisone—psoriasis	6.97e-06	5.19e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—psoriasis	6.96e-06	5.18e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—psoriasis	6.96e-06	5.18e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—psoriasis	6.86e-06	0.000253	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CARM1—psoriasis	6.82e-06	0.000251	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STAT3—psoriasis	6.8e-06	0.000251	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—IL6—psoriasis	6.78e-06	0.00025	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CAT—psoriasis	6.74e-06	0.000248	CbGpPWpGaD
Tacrolimus—Vomiting—Prednisone—psoriasis	6.7e-06	4.99e-05	CcSEcCtD
Tacrolimus—Rash—Prednisone—psoriasis	6.64e-06	4.95e-05	CcSEcCtD
Tacrolimus—Dermatitis—Prednisone—psoriasis	6.64e-06	4.94e-05	CcSEcCtD
Tacrolimus—Headache—Prednisone—psoriasis	6.6e-06	4.92e-05	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL8—psoriasis	6.55e-06	0.000242	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TYK2—psoriasis	6.55e-06	0.000241	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Methotrexate—psoriasis	6.49e-06	4.83e-05	CcSEcCtD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.37e-06	0.000235	CbGpPWpGaD
Tacrolimus—Asthenia—Methotrexate—psoriasis	6.32e-06	4.71e-05	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.26e-06	0.000231	CbGpPWpGaD
Tacrolimus—Nausea—Prednisone—psoriasis	6.26e-06	4.66e-05	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—psoriasis	6.23e-06	4.64e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—IFNG—psoriasis	6.13e-06	0.000226	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—JUN—psoriasis	6.09e-06	0.000225	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TYK2—psoriasis	6.04e-06	0.000223	CbGpPWpGaD
Tacrolimus—Diarrhoea—Methotrexate—psoriasis	6.02e-06	4.49e-05	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—CARM1—psoriasis	5.97e-06	0.00022	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD4—psoriasis	5.92e-06	0.000218	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NFKB1—psoriasis	5.86e-06	0.000216	CbGpPWpGaD
Tacrolimus—Dizziness—Methotrexate—psoriasis	5.82e-06	4.34e-05	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—psoriasis	5.6e-06	4.17e-05	CcSEcCtD
Tacrolimus—Rash—Methotrexate—psoriasis	5.55e-06	4.14e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—LEP—psoriasis	5.55e-06	0.000205	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOE—psoriasis	5.55e-06	0.000205	CbGpPWpGaD
Tacrolimus—Dermatitis—Methotrexate—psoriasis	5.55e-06	4.13e-05	CcSEcCtD
Tacrolimus—Headache—Methotrexate—psoriasis	5.51e-06	4.11e-05	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—IL6—psoriasis	5.5e-06	0.000203	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—psoriasis	5.47e-06	0.000202	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—psoriasis	5.32e-06	0.000196	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—JUN—psoriasis	5.3e-06	0.000195	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—psoriasis	5.27e-06	0.000194	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—psoriasis	5.26e-06	0.000194	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOE—psoriasis	5.23e-06	0.000193	CbGpPWpGaD
Tacrolimus—Nausea—Methotrexate—psoriasis	5.23e-06	3.9e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—psoriasis	5.19e-06	0.000191	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NFKBIA—psoriasis	5.17e-06	0.000191	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NFKB1—psoriasis	5.1e-06	0.000188	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CAT—psoriasis	4.87e-06	0.00018	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—psoriasis	4.75e-06	0.000175	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—psoriasis	4.58e-06	0.000169	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—psoriasis	4.56e-06	0.000168	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—psoriasis	4.34e-06	0.00016	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TYK2—psoriasis	4.23e-06	0.000156	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—psoriasis	4.23e-06	0.000156	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CAT—psoriasis	4.19e-06	0.000155	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—psoriasis	4.02e-06	0.000148	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOE—psoriasis	3.78e-06	0.00014	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—psoriasis	3.69e-06	0.000136	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—psoriasis	3.68e-06	0.000136	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CARM1—psoriasis	3.68e-06	0.000136	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CAT—psoriasis	3.67e-06	0.000136	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JUN—psoriasis	3.43e-06	0.000126	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NFKB1—psoriasis	3.3e-06	0.000122	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—psoriasis	3.3e-06	0.000122	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—psoriasis	3.28e-06	0.000121	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOE—psoriasis	3.26e-06	0.00012	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—psoriasis	3.2e-06	0.000118	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—psoriasis	2.99e-06	0.00011	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—psoriasis	2.96e-06	0.000109	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—psoriasis	2.96e-06	0.000109	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOE—psoriasis	2.85e-06	0.000105	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—psoriasis	2.84e-06	0.000105	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—psoriasis	2.49e-06	9.17e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CAT—psoriasis	2.26e-06	8.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—psoriasis	2.26e-06	8.34e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—psoriasis	2.07e-06	7.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOE—psoriasis	1.76e-06	6.49e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—psoriasis	1.53e-06	5.65e-05	CbGpPWpGaD
